Cui Yong-Qi, Geng Qin, Yu Tao, Zhang Fang-Lin, Lin He-Chun, Li Jing, Zhu Miao-Xin, Liu Lei, Yao Ming, Yan Ming-Xia
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200032, P.R. China.
Int J Oncol. 2015 Sep;47(3):927-40. doi: 10.3892/ijo.2015.3065. Epub 2015 Jun 26.
Lung cancer is the leading cause of malignancy-related death worldwide, and metastasis always results in a poor prognosis. However, therapeutic progress is hampered by a deficiency of appropriate pre-clinical metastatic models. To bridge this experimental gap, we developed an in vivo metastatic model via subcutaneous (s.c.) injection. The original cell line (XL-2) adopted in this model was newly isolated from the ascites of a patient with extensive metastases of lung adenocarcinoma, thereby avoiding any alteration of its initial molecular biology features from artificial serial cultivation. After comprehensive phenotypical and histological analysis, it was identified as a lung adenocarcinoma cell line. Additionally, the drug test showed that XL-2 cell line was sensitive to docetaxel, and resistant to doxorubicin, indicating it might serve as a cell line model of drug resistance for identifying mechanisms of tumors resistant to doxorubicin. Through this s.c. model, we further obtained a highly metastatic cell line (designated XL-2sci). The metastatic rate of mice in XL-2 group was 3/10, in contrast to the rate of 9/10 in XL-2sci group. Optical imaging, micro-computed tomography (micro-CT) scanning and Transwell assays were further applied to identify the enhanced metastatic capacity of Xl-2sci cells both in vivo and in vitro. Compared with XL-2 cells, ITRAQ labeled proteomics profiling study showed that some tumor metastasis-associated proteins were upregulated in XL-2sci cells, which also indicated the reliability of our model. Proliferation ability of XL-2 and XL-2sci were also evaluated. Results showed that highly metastatic XL-2sci possessed a decreased proliferation capacity versus XL-2, which demonstrated that its increased metastatic activity was not facilitated by a faster growth rate. In conclusion, we successfully developed an in vivo metastatic model using a newly established lung adenocarcinoma cell line, which will be beneficial to further investigations of lung cancer metastasis and to the development of anti-metastasis drugs.
肺癌是全球恶性肿瘤相关死亡的主要原因,而转移通常会导致预后不良。然而,由于缺乏合适的临床前转移模型,治疗进展受到阻碍。为了弥补这一实验差距,我们通过皮下注射开发了一种体内转移模型。该模型采用的原始细胞系(XL-2)是从一名肺腺癌广泛转移患者的腹水中新分离出来的,从而避免了因人工传代培养而导致其初始分子生物学特征发生任何改变。经过全面的表型和组织学分析,它被鉴定为肺腺癌细胞系。此外,药物测试表明XL-2细胞系对多西他赛敏感,对阿霉素耐药,这表明它可能作为一种耐药细胞系模型用于确定肿瘤对阿霉素耐药的机制。通过这个皮下模型,我们进一步获得了一个高转移细胞系(命名为XL-2sci)。XL-2组小鼠的转移率为3/10,而XL-2sci组为9/10。进一步应用光学成像、微型计算机断层扫描(micro-CT)和Transwell实验来确定Xl-2sci细胞在体内和体外的转移能力增强。与XL-2细胞相比,ITRAQ标记的蛋白质组学分析研究表明,一些肿瘤转移相关蛋白在XL-2sci细胞中上调,这也表明了我们模型的可靠性。还评估了XL-2和XL-2sci的增殖能力。结果表明,高转移的XL-2sci与XL-2相比增殖能力下降,这表明其转移活性的增加并非由更快的生长速度所促进。总之,我们成功地利用新建立的肺腺癌细胞系开发了一种体内转移模型,这将有助于进一步研究肺癌转移和抗转移药物的开发。